Source: Annual Congress 2004 - Pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. U. Rybacka-Chabros, J. Milanowski, Z. M. Chabros, J. Karski (Lublin, Poland). Possible anti-inflammatory activity of low molecular weight heparin in patients with high risk of pulmonary embolism. Eur Respir J 2004; 24: Suppl. 48, 4188

Member's Comments

No comment yet.

Related content which might interest you: Anti-inflammatory activity of low molecular weight heparin in patients with exacerbations of COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 How to identify patients with low risk pulmonary embolism Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007 A prospective study of the use of low molecular weight heparin for prevention of venous thrombo-embolism in breathless patients with limited mobility Source: Annual Congress 2009 - Intensive care unit management and outcome Year: 2009 Pulmonary embolism and pregnancy Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177 Year: 2004 Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism Source: Annual Congress 2003 - Pulmonary hypertension Year: 2003 Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007 Early discharge of patients with pulmonary embolism: a two-phase observational study Source: Eur Respir J 2007; 30: 708-714 Year: 2007 Plasma high fibrinogen and low plasminogen levels predict poor prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Long term treatment of pulmonary embolism (PE) with low molecular weight heparin (LMWH) (tinzaparin). Preliminary results Source: Eur Respir J 2007; 30: Suppl. 51, 80s Year: 2007 Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020 Comparison between airway response to high versus low molecular weight agents in occupational asthma Source: Annual Congress 2010 - Occupational asthma Year: 2010 Low body mass index in hospitalised patients with chronic obstructive pulmonary disease (COPD): is related to low lung function and increased mortality Source: Eur Respir J 2006; 28: Suppl. 50, 66s Year: 2006 High incidence of bacteraemia complicating iv prostaglandin therapy in patients with pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 371s Year: 2002 Effect of vascular endothelial growth factor antisense oligonucleotides and low molecular weight heparin on pulmonary thromboembolism in mice with Lewis lung cancer Source: Annual Congress 2006 - Lung cancer staging and miscellaneous Year: 2006 The genetic risk factors for the recurrent pulmonary embolism Source: Eur Respir J 2005; 26: Suppl. 49, 100s Year: 2005 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014 Increased incidence of pulmonary embolism in severe asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Modification of the simplified PESI score to identify low risk patients with acute symptomatic pulmonary embolism Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019